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Abstract
Studies in several sub-Saharan African countries demonstrated that the expansion of antiretroviral therapy (ART)
access is not only beneficial for people living with HIV, but also results in significant declines in tuberculosis and
malaria incidence and prevalence, bolstering arguments for earlier and increased ART access and contributing to a
growing understanding of co-epidemic dynamics. Several studies demonstrated that using standard triple-drug ART
in resource-limited settings can reduce vertical transmission by as much as less than 1% if continued throughout
breastfeeding.
The Nevirapine Resistance Study (NEVEREST) results provided proof of concept that nevirapine could be used as
part of a paediatric second-line regimen, despite exposure to nevirapine prophylaxis for vertical transmission,
following successful suppression on a lopinavir/ritonavir-based regimen. A South African study found that high
pre-treatment levels of inflammatory and coagulation markers were strong predictors of death, reflecting similar
findings in high-income countries and reinforcing the shift towards viewing HIV as a chronic, inflammatory disease.
An early study of a new integrase inhibitor (S/GSK1349572) indicated strong potency and limited cross-resistance
with raltegravir, the only integrase inhibitor currently approved for treatment.
Discussion
Advances reported in clinical research at the 5
th Inter-
national AIDS Society Conference on HIV Pathogenesis,
Treatment and Prevention (IAS 2009) could have a pro-
found impact on global and national policies guiding
antiretroviral initiation. Salient studies detailed the effect
of triple-drug ART on co-epidemic tuberculosis (TB)
and malaria and on prevention of vertical transmission.
Other work reviewed by Track B lead rapporteur Pablo
Tebas (University of Pennsylvania, Philadelphia) detailed
progress in understanding the role of inflammation on
HIV and non-HIV disease progression, and outlined
findings on a potent new integrase inhibitor [1].
Treating HIV can curb TB and malaria
A comparison of 2005 and 2008 TB and HIV rates in a
well-defined South African township yielded strong evi-
dence that wider ART accounts for a significant decline
in TB prevalence in both HIV-infected and HIV-unin-
fected individuals [2]. Analyzing TB rates in 762 people
surveyed in 2005 and 1251 surveyed in 2008, Keren
Middelkoop (University of Ca p eT o w n )f o u n dt h a tT B
prevalence fell by more than one-third, from 3% in 2005
to 1.8% in 2008, a significant decline in an analysis
adjusted for age, gender and HIV status.
Decreasing TB prevalence could be traced almost
entirely to HIV-positive people in the township, where
antiretroviral access expanded greatly from 2005 to
2008. Other potential explanations of the falling TB rate
did not withstand scrutiny. In addition, a small but sig-
nificant decline in TB incidence was also observed
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suggesting that the community-wide benefit of ART
extended even to those without HIV infection.
SM Hermans (University Medical Center, Utrecht)
determined TB incidence and risk factors in 360 of 7648
ART-treated Ugandan patients with a new TB diagnosis
within two years of starting ART or starting TB drugs
within two years of ART initiation [3]. TB incidence fell
from 9.91 cases per 100 person-years zero to three
months after starting ART to 5.14 cases after three to
six months, 2.16 cases after six to 12 months, and 0.82
cases after 12 to 24 months. Beginning ART with a CD4
count below 50 cells/mm
3 versus at least 200 cells/mm
3
independently raised the risk of TB by 58% (P=0.01),
while male gender independently raised the risk by 43%
(P=0.001). Beginning treatment with efavirenz plus zido-
vudine/lamivudine compared with nevirapine plus stavu-
dine/lamivudine lowered the TB risk by 33% (P=0.002).
The association between an efavirenz regimen and lower
TB risk is striking because clinicians tend to avoid efa-
virenz in patients with TB symptoms to avoid switch-
ing from efavirenz if the patient has to begin rifampicin
for TB.
A prospective Ugandan cohort study traced a steeply
declining malaria incidence after ART initiation, from
591 cases per 100 person-years after one year to 476
cases after two years, 259 cases after three years, and
153 cases after four years [4]. Rogers Kasirye (MRC/
UVRI Uganda Research Unit on AIDS, Entebbe)
counted 524 new cases of malaria in 1020 patients
enrolled in the Development of Anti-Retroviral Therapy
in Africa (DART) trial. Pre-ART CD4 count below
10 cells/mm
3, younger age and less education correlated
with a higher malaria risk, while cotrimoxazole prophy-
laxis lowered the risk.
ART cuts vertical transmission rate below 1% during
breastfeeding
In a randomized Botswana trial, triple-drug ART for
mothers with HIV lowered vertical transmission during
breastfeeding to less than 1%, the lowest rate ever
recorded in nursing infants [5]. Roger Shapiro (Harvard
University, Boston) and Mma Bana trial colleagues stu-
died 730 women, 560 of them with a CD4 count above
199 cells/mm
3 and randomized to coformulated abaca-
vir/zidovudine/lamivudine or lopinavir/ritonavir plus
zidovudine/lamivudine. The remaining women, all with
fewer than 200 cells/mm
3, took nevirapine with zidovu-
dine/lamivudine. All women began ART from 26 to 34
weeks gestation and aimed to continue until six months
after delivery, when rapid weaning was advised. Viral
suppression rates were greater than 90% with all three
regimens at delivery and throughout breastfeeding. Only
seven HIV transmissions occurred through six months
after delivery for an overall transmission rate of 1%.
Two Track C studies also documented lower vertical
transmission rates with maternal highly active antiretro-
viral therapy (HAART) than with no intervention or
other interventions during breastfeeding, including the
2367-infant randomized Breastfeeding, Antiretroviral
and Nutrition (BAN) trial (Figure 1) [6], and the rando-
mized Kesho Bora trial involving 805 infants in Burkina
Faso and Kenya [7].
First- and second-line ART for infants in resource-poor
settings
Results of a randomized South African trial could reshape
early ART planning for infants and children exposed to
single-dose nevirapine (sdNVP) at birth if the findings are
confirmed [8]. Current national and international guide-
lines for children exposed to sdNVP call for a first-line
regimen including the protease inhibitors (PIs), lopinavir/
ritonavir, because infants infected despite sdNVP often
have virus resistant to the non-nucleosides, nevirapine and
efavirenz. But nevirapine-based regimens are cheaper and
easier to use than lopinavir/ritonavir regimens because
nevirapine is formulated with other antiretrovirals as a sin-
gle generic pill.
The NEVEREST study involved 322 HIV-positive chil-
dren under two years old who had received sdNVP.
Children who reached a viral load below 400 copies/mL
after three months of treatment with a lopinavir/ritona-
vir combination were randomized to continue that regi-
men or substitute nevirapi n ef o rt h eP I s .S i xm o n t h s
after randomization, significantly more children who
switched to nevirapine maintained a viral load below 50
copies, although more children who stayed with lopina-
vir/ritonavir consistently maintained a viral load below
1000 copies/mL. The NEVEREST investigators believe
their results provide “proof of concept that re-use of
nevirapine following successful suppression on lopina-
vir/ritonavir-based therapy is possible under some cir-
cumstances for HIV-infected children exposed to
nevirapine prophylaxis”.
A study of 5484 children under 16 years old starting
their first ART in sub-Saharan Africa found that only
11.4% met virologic failure criteria (consecutive viral
loads above 10,000 copies/mL) more than five months
after beginning treatment (Figure 2) [9]. (The investiga-
tors chose that liberal definition of failure as a starting
point in defining failure in children.) Beginning ART
with more advanced HIV infection or with ritonavir as
the only PI independently raised the risk of failure.
Among 146 children remaining in care for at least one
year after failure, only 62 (42%) switched to a second-
line regimen. Median time between failure and switch
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Figure 1 Probability HIV positive or death by week 28 visit in infants uninfected at birth. Source: Chasela C, et al: Both maternal HAART
and daily infant nevirapine (NVP) are effective in reducing HIV-1 transmission during breastfeeding in a randomized trial in Malawi:
28 week results of the Breastfeeding, Antiretroviral and Nutrition (BAN) Study. 5th IAS Conference on HIV Pathogenesis, Treatment and
Prevention: Cape Town, South Africa. WELBC103 [6].
Figure 2 Virologic failure and second-line ART in children in South Africa. Source: Davies MA, et al: Virologic failure and second-line
antiretroviral therapy (ART) in children in South Africa: the international epidemiologic databases to evaluate AIDS (IeDEA) Southern
Africa collaboration. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Cape Town, South Africa. MOAB104. [9]
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children had an undetectable viral load.
Inflammation markers predict death on ART in South
Africa
Higher levels of inflammatory and coagulation markers are
strongly related to death from any cause in people taking
ART in developed countries [10]. Pre-ART levels of some
of the same markers predicted death after ART began in a
randomized trial involving 1771 members of the South
African Defence Force and their dependents [11]. Lotty
Ledwaba (Project Phidisa, Pretoria) conducted a case-con-
trol comparison nested in a randomized trial comparing
different antiretroviral regimens. Matching each person
who died (cases) with two people who did not die (con-
trols) by date of randomization, follow-up time, study site
and CD4 count, Ledwaba found significantly higher pre-
treatment levels of two inflammation markers (C-reactive
protein and interleukin-6) and one coagulation marker
(D-dimer) in cases. Ledwaba suggested “aggressive clinical
monitoring” may be warranted in patients beginning ART
with high levels of these markers.
New integrase inhibitor surprises with potency
Promising results were reported on a new integrase
inhibitor (S/GSK1349572) with a resistance profile dif-
ferent from those of raltegravir and elvitegravir [12].
A double-blind trial enrolled 35 HIV-positive adults
with a viral load above 5000 copies/mL, no integrase
inhibitor experience, and no ART for the past 12 weeks.
Study participants were randomized to 10 days of
monotherapy with 2, 10, or 50mg of S/GSK1349572 or
to placebo. Viral load declined 2.5 log in the 50mg
group, more than in any previous antiretroviral mono-
therapy study. Seven of 10 people taking 50mg had a
viral load below 50 copies/mL on day 11, and nine had
fewer than 400 copies/mL. Other studies reported at the
conference demonstrated limited cross-resistance
between S/GSK1349572 and raltegravir, the only mar-
keted integrase inhibitor [13,14].
Conclusions
Especially in countries with high TB prevalence, starting
ART may raise the risk of clinical TB in the short term
because ART-induced immune reconstitution can
unmask latent TB by restoring TB-specific immune
responses [15]. But two studies at this conference [2,3]
found a strong correlation between ART and falling TB
rates over the long term. These findings should temper
concerns about beginning ART in TB-prevalent coun-
tries and, indeed, argue for wider ART access and earlier
ART in such populations. As IAS 2009 ended, South
African health authorities said they would consider pro-
viding ART to everyone coinfected with HIV and TB.
In a similar way, sharply falling malaria incidence
throughout the first years of ART [4] bolsters the ratio-
nale for wider and earlier ART in populations with high
malaria rates. In people not taking antiretrovirals,
malaria raises HIV-1 RNA levels [16] and weakens the
immune system [17].
Research like this exposes the weakness of arguments
against sustained funding of HIV research because it
“robs” from studies of other epidemic diseases. When-
ever epidemics feed each other – as HIV, TB, and
malaria do – understanding one can only lead to better
control of the others. There is growing evidence, out-
lined in the additional file 1, that the infusion of sup-
port for HIV-related prevention, care and treatment
services is improving non-HIV-related health indica-
tors worldwide.
Consistently low vertical transmission rates when
mothers begin standard triple-drug ART during preg-
nancy and continue through breastfeeding [5-7] argue
strongly for rapid revision of antiretroviral guidelines
during pregnancy, delivery and nursing. The World
Health Organization is considering these results and
others with an eye toward revamping treatment advice,
and national guideline bodies should do the same.
The two studies of ART in infants and children break
new ground in defining treatment responses in countries
with high HIV prevalence. The randomized trial of
nevirapine versus lopinavir/ritonavir after viral control
with the latter in sdNVP-exposed children offers the
first evidence that nevirapine may be a sound treatment
option in children already given nevirapine in an unsuc-
cessful attempt to prevent vertical transmission [8].
Nevirapine is less expensive and more convenient than
lopinavir/ritonavir, and it usually has fewer long-term
side effects, which is an important consideration for
children facing many years of ART.
The study of switching antiretrovirals after first-line
failure in children raises several concerns [9]. The nearly
five-month average delay between confirmed virologic
failure and starting a new regimen could easily open the
door to resistant virus, which readily emerges when a
failing regimen continues. Yet the delay reflects clinical
realities in resource-poor settings, where more time is
often needed to confirm failure and to discern the
cause. Clinicians may also be less apt to prescribe sec-
ond-line treatment in clinics with limited second-line
options. Results of this important study underscore the
need for routine and timely virologic monitoring in low-
and middle-income countries and the urgency of provid-
ing additional treatment options.
The finding that pre-ART inflammation and coagula-
tion markers predict death on ART in South African
patients [11] extends similar findings in developed-coun-
try cohorts [10] and confirms the need to pursue
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similarities and differences. Concordant findings in this
area, lead rapporteur Pablo Tebas bluntly concluded,
indicate that “inflammation is really important” in
understanding disease progression and mortality in
people with HIV.
In a plenary address on this topic, Wafaa El-Sadr
(Columbia University, New York) called the dawning
recognition of how uncontrolled HIV permits ongoing
inflammation a “paradigm shift” [18]. She cited numer-
ous studies showing that HIV replication induces activa-
tion of tissue factor pathways, thrombosis and
fibrinolysis, which are all associated with an increased
risk of all-cause mortality.
The 10-day monotherapy study of the potent investi-
gational integrase inhibitor, S/GSK1349572, demon-
strates the value of continued antiretroviral development
[12]. The past few years witnessed the arrival of several
strong and tolerable antiretrovirals in new and existing
classes. There is no reason to assume that even better
drugs cannot be developed.
Additional file 1: HIV investments demonstrate benefits for other
diseases and increased uptake in non-HIV-related health
servicesHIV investments demonstrate benefits for other diseases
and increased uptake in non-HIV-related health services
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